Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioLineRx Ltd. Capital/Financing Update 2013

May 17, 2013

6692_rns_2013-05-17_b14dfca8-05be-4b53-b841-9330fe9d4896.htm

Capital/Financing Update

Open in viewer

Opens in your device viewer

_________ false

C003������� �� ��� ��"�2PublicBIOLINE RX LTD9253Corporation no: 513398750Stock Exchange/Market: NASDAQ-SC2271381����� 19 , ������� 91450 , ,Tel: 02-5489100 , 02-5489116 Fax: 02-5489101E.mail address: [email protected] of transmission: 17/05/2013              Time of broadcast: 20:16 20:12:23

Reference: 2013-02-063601

Israel Securities Authority Tel Aviv Stock Exchange
www.isa.gov.il www.tase.co.il

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on Prospectus Supplement

424b5_ATM_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2012-02-211239
Previous names of reporting entity:
Date of revision of form structure: 05/05/2013
- - -
Name of the Signatory: : Kotler Norman Harold , Position of Signatory in the reporting corporation: General Counsel & Company Secretary , Name of Employer Company: .
Hartum Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: [email protected] 1